Hello, I'm Greg Jenna and good news, Your Dead to Me is back for a new series. Here we go. Yes, we'll explore Emperor Nero's notorious reign with Professor Marybeard and Patton Oswald. I would not want my daughter having the remote control, not alone an empire. We'll dissect the decadent life of Philippe Duke-Dor-Leon with Tom Allen. I've often tried to pretend I'm an aristocrat and being very quickly knocked down. And there'll be so much more with comedians like Olga Koch, Mike Mosniak and Rihalina. I'm excited. You're dead to me, the comedy podcast that takes history seriously. Listen first on BBC Sounds. Hello, thank you for listening to this edition of Inside Health. I hope you enjoy it. Coming up in today's program, why an aspirin a day might not keep the doctor away.

We found that the risk increased very steeply over 70 and particularly over 75,

so that it was about three times more likely that you'd have a major bleed on aspirin over 75 than under 75. And it was about five times more likely that you'd have a major bleed on aspirin over 75 than under 75,

and it was about five times more likely that you'd have a disabling or fatal bleed.

And paradoxically, stopping aspirin suddenly can be bad for you too.

More from Professor Peter Rothwell later.

And platelets could a simple blood test available in all GP surgeries help identify

underlying cancers. But first, allegations of profiteering in the NHS. The Health Service

spends a fortune on medicines, around £16 billion a year in England alone. But it could be spending more than it needs to

if there's any substance to growing concerns that some drug manufacturers are exploiting monopolies.

We've been contacted by pharmacist Ben Merriman, who calculated just how much these often

unexplained price hikes were costing the NHS in his home county of Cumbria,

and it's a lot.

We investigated the meteoric rises of the prices of some everyday medicines

last year on Inside Health, and back then,

were told by the British Generic Manufacturers Association

that it only affected a very small number of products,

and at least two had been referred to the competition regulator for investigation.

Well, nearly a year on and not much seems to have changed, according to Ben.

Over the last three or four years or so,

I've noticed that there are several relatively commonly used drugs

that have had really quite large price increases on them.

...